Myra Vision announced that the first patient has been enrolled in its ADAPT clinical study, a US-based investigation evaluating the company’s investigational Calibreye Titratable Glaucoma Therapy Surgical System. The enrollment follows the FDA’s approval of an investigational device exemption in August 2025, allowing the study to proceed.

ADAPT is a prospective, multicenter, nonrandomized, open-label trial that plans to enroll up to 70 patients with refractory glaucoma. The primary effectiveness endpoint is 12 months. The study will assess the safety and effectiveness of the Calibreye system, an aqueous shunt designed to allow postoperative adjustment of outflow using a slit lamp as patient needs change over time.

The Calibreye system is intended for patients with moderate to severe glaucoma who require substantial intraocular pressure reduction. Unlike traditional tube shunts or trabeculectomy, the device is designed to permit clinician-directed titration after implantation. Data from a feasibility study presented at last year's American Glaucoma Society meeting suggested that the Calibreye system may offer significant IOP and medication reduction with potential for in-office adjustments as needed. GP